Nerve Grafting Technique to Preserve Erectile Function in Patients Undergoing Robotic Assisted Radical Prostatectomy
Launched by SIR MORTIMER B. DAVIS - JEWISH GENERAL HOSPITAL · Jul 25, 2024
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new surgical technique called Nerve Restoring Robotically Assisted Laparoscopic Prostatectomy (NR-RALP) to help men keep their ability to have erections after surgery for prostate cancer. The study will involve 10 men who are scheduled for robotic prostate surgery, and it aims to assess the safety of this new method as well as how well it helps with erectile recovery one year after the procedure. By using a special nerve graft, the researchers hope to improve the chances of erectile function recovery while reducing any additional complications from surgery.
To participate in this trial, men should be between the ages of 65 and 74, have high-risk localized prostate cancer, and have had some level of erectile function before surgery. This means they should have a specific score indicating erectile function of 17 or higher. However, men with previous pelvic surgeries, certain medical conditions, or other treatments for prostate cancer may not be eligible. Participants can expect to undergo the new surgical technique and will be followed for a year to see how well their erectile function recovers. It's a promising study that could offer new hope for men facing prostate cancer surgery.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- 1. Patients undergoing standard of care robotic radical prostatectomy for high-risk localized prostate cancer as defined by any of:
- • 1. Gleason grade ≥8
- • 2. PSA ≥20
- • 3. \>pT2 on preoperative MRI imaging
- • 2. Patients must have preoperative erectile function with a baseline IIEF score of ≥17
- Exclusion Criteria:
- • 1. Patients with previous pelvic surgery
- • 2. Patients with previous pelvic radiotherapy
- • 3. Patient with previous focal therapy for prostate cancer
- • 4. Patients aged \< 18 years at diagnosis
- • 5. Legally incapable patients
- • 6. Patients who are unable to complete questionnaires and have no companion to help complete them
- • 7. Patients undergoing a concomitant cancer surgery
- • 8. Patients with pre-existing neurologic disease
About Sir Mortimer B. Davis Jewish General Hospital
Sir Mortimer B. Davis – Jewish General Hospital is a leading academic medical center located in Montreal, Canada, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical research, the hospital integrates cutting-edge scientific inquiry with comprehensive patient care, focusing on a range of medical disciplines to enhance treatment outcomes and improve patient quality of life. With a strong emphasis on collaboration, ethics, and community engagement, the hospital strives to foster a research environment that promotes discovery and translates findings into effective therapeutic solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montréal, Quebec, Canada
Montreal, Quebec, Canada
Patients applied
Trial Officials
Victor McPherson, MD
Principal Investigator
Jewish General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported